Close Menu

NEW YORK — Molecular Health said on Tuesday that it has signed an agreement to use its MH BRCA and MH Mendel precision medicine software to help Japanese clinical testing firm Falco Biosystems evaluate disease-associated genes for its customers.

Part of Molecular Health's Guide sequencing data-analysis platform for personalized medicine, MH BRCA identifies and reports on inherited variants in BRCA1, BRCA2, and other genes linked to breast and ovarian cancer, while MH Mendel can analyze for a broader range of hereditary disease.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Sponsored by

Recent advances in single-cell technologies have provided unprecedented -omic-level insights into cellular heterogeneity and function. 

Sponsored by

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Sponsored by
Akoya Biosciences

Single-cell omics assays have become essential tools for identifying and characterizing cell types and states of complex tissues. While each single-modality assay reveals distinctive features about the sequenced cells, true multiomics assays are still in the early stage of development. 

Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.